Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026)

Alnylam Pharmaceuticals has reported Convertible Debt for 5 years, with the latest figure at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt fell 1.58% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (down 1.58% YoY), and the FY2025 full-year result was $1.0 billion, down 1.64% from the prior year.
• Convertible Debt for Q1 2026 stood at $1.0 billion, roughly flat from $1.0 billion in the prior quarter.
• The five-year high for Convertible Debt was $1.0 billion in Q3 2025, with the low at $1.0 billion in Q4 2025.
• Historically, Convertible Debt has averaged $1.0 billion across 5 years, with a median of $1.0 billion in 2023.
• The largest YoY upside for Convertible Debt was 1.62% in 2025 against a maximum downside of 1.64% in 2025.
• Alnylam Pharmaceuticals' Convertible Debt stood at $1.0 billion in 2022, then increased by 0.38% to $1.0 billion in 2023, then rose by 0.38% to $1.0 billion in 2024, then retreated by 1.64% to $1.0 billion in 2025, then rose by 0.16% to $1.0 billion in 2026.
• The last three Convertible Debt figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.